While there is no basis to speculate that the activity of chemotherapy could be compromised by this mutation, the possibility that immunotherapy may be less effective is theoretically justified by the evidence that some driver alterations reduce the efficacy of anti-PD(L)1 in other solid tumors, particularly in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.